2020
Association of 21-Gene Assay (OncotypeDX) Testing and Receipt of Chemotherapy in the Medicare Breast Cancer Patient Population Following Initial Adoption
Dinan MA, Wilson LE, Reed SD, Griggs JJ, Norton EC. Association of 21-Gene Assay (OncotypeDX) Testing and Receipt of Chemotherapy in the Medicare Breast Cancer Patient Population Following Initial Adoption. Clinical Breast Cancer 2020, 20: 487-494.e1. PMID: 32653473, DOI: 10.1016/j.clbc.2020.05.010.Peer-Reviewed Original Research
2018
Real-world systemic therapy utilization in Medicare patients with locally advanced or metastatic urothelial carcinoma.
Dinan M, Georgieva M, Shenolikar R, Scales C. Real-world systemic therapy utilization in Medicare patients with locally advanced or metastatic urothelial carcinoma. Journal Of Clinical Oncology 2018, 36: 415-415. DOI: 10.1200/jco.2018.36.6_suppl.415.Peer-Reviewed Original ResearchMetastatic urothelial carcinomaMedicare patientsUrothelial carcinomaInitial chemotherapyPlatinum-doublet regimenAdvanced urothelial carcinomaDistant metastatic diseasePlatinum-containing chemotherapyReceipt of chemotherapyMetastatic bladder cancerYear of diagnosisCongestive heart failureGemcitabine/carboplatinGemcitabine/cisplatinUpper urinary tractCharacterized patientsDoublet chemotherapyNeoadjuvant chemotherapyDoublet regimenMetastatic diseaseMost patientsSystemic therapyHeart failureRenal diseaseComorbid conditions
2015
Association Between Use of the 21-Gene Recurrence Score Assay and Receipt of Chemotherapy Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005-2009
Dinan MA, Mi X, Reed SD, Lyman GH, Curtis LH. Association Between Use of the 21-Gene Recurrence Score Assay and Receipt of Chemotherapy Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005-2009. JAMA Oncology 2015, 1: 1098. PMID: 26313372, DOI: 10.1001/jamaoncol.2015.2722.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAntineoplastic AgentsBiomarkers, TumorBreast NeoplasmsChemotherapy, AdjuvantChi-Square DistributionFemaleGene Expression ProfilingGenetic Predisposition to DiseaseGenetic TestingGuideline AdherenceHumansInsurance BenefitsMedicareMultivariate AnalysisNeoplasm Recurrence, LocalNeoplasm StagingOdds RatioPatient SelectionPhenotypePractice Guidelines as TopicPredictive Value of TestsRetrospective StudiesRisk AssessmentRisk FactorsSEER ProgramTime FactorsTreatment OutcomeUnited StatesConceptsReceipt of chemotherapyLower chemotherapy useHigh-risk diseasePatients 70 yearsChemotherapy useBreast cancerRecurrence scoreMedicare beneficiariesNational Comprehensive Cancer Network guidelinesEarly-stage breast cancerConsideration of chemotherapyLow-risk diseaseOverall chemotherapy useIncident breast cancerLow-risk patientsRetrospective cohort studyHigh-risk patientsPrespecified subgroup analysisUse of chemotherapyAdditional prognostic informationEnd Results (SEER) dataInvasive breast cancerRS assayNCCN riskAdjuvant chemotherapy
2014
Association between Oncotype DX and receipt of chemotherapy in early-stage breast cancer within the Medicare population from 2004 to 2007.
Dinan M, Mi X, Reed S, Lyman G, Curtis L. Association between Oncotype DX and receipt of chemotherapy in early-stage breast cancer within the Medicare population from 2004 to 2007. Journal Of Clinical Oncology 2014, 32: 309-309. DOI: 10.1200/jco.2014.32.30_suppl.309.Peer-Reviewed Original ResearchReceipt of chemotherapyChemotherapy utilizationOncotype DXRisk diseaseBreast cancerODX testingEarly-stage estrogen receptor-positive breast cancerEstrogen receptor-positive breast cancerReceptor-positive breast cancerEarly-stage breast cancerER-positive breast cancerIntermediate-risk diseaseHigh-risk patientsHigh-risk diseasePositive breast cancerBreast cancer populationAdjuvant chemotherapyNCCN guidelinesRisk patientsPathologic featuresRandomized trialsStudy criteriaCancer populationObservational studyRetrospective analysis